Pharma Industry 4.0: Literature review and research opportunities in sustainable pharmaceutical supply chains
•The sustainable pharmaceutical supply chain (PSC) management is still a niche area for both pharmaceutical and supply chain management researchers. The exploitation of the emerging technologies of Pharma Industry 4.0 facilitates sustainable value creation, leads to more agile, smart and personalise...
Gespeichert in:
Veröffentlicht in: | Process safety and environmental protection 2018-10, Vol.119, p.115-130 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 130 |
---|---|
container_issue | |
container_start_page | 115 |
container_title | Process safety and environmental protection |
container_volume | 119 |
creator | Ding, Baoyang |
description | •The sustainable pharmaceutical supply chain (PSC) management is still a niche area for both pharmaceutical and supply chain management researchers. The exploitation of the emerging technologies of Pharma Industry 4.0 facilitates sustainable value creation, leads to more agile, smart and personalised pharma industry.•A more sustainable PSC should be applied to match future smart operations and management of the pharmaceutical products across the entire life cycle, from manufacturing to end-users. However, both internal and external inhibitors should be overcome, which include: high investment; poor support by senior managers; lack of well training expertise; enforcement of regulations; the insufficient coordination and communication beyond the boundaries of the PSC; the paucity of assessment systems and benchmarks; ineffective business incentives; poor end-customer awareness.•The sustainable PSC can benefit from Industry 4.0 in terms of four main aspects: enhancing the flexibility of the PSC for patient-centric drug supplies; improving the effectiveness of coordination and communication across different entities; reducing waste and pollution at different stages; and enabling a more autonomous decision-making process for supply chain managers, especially for healthcare sectors.•Future research interest can concentrate on: cross-linking coordination and cooperation, eco-friendly end-of-life products disposal, proactive recall management, new benchmarks and measurement of sustainable performance, new regulation system design, and effects of incentives for sustainable activities.
The exploitation of the emerging technologies of Pharma Industry 4.0 facilitates sustainable value creation, leads to more agile, smart and personalised pharma industry, and thereby, in the long-run, enables pharma companies to obtain competitive advantages. A more sustainable pharmaceutical supply chain (PSC) should be implemented to match future operations and management of the pharmaceutical products across the entire life cycle. The main purpose of this study is to identify the potential sustainability barriers of PSC and to investigate how Industry 4.0 can be applied in the sustainable PSC paradigms. This paper systematically reviews 33 relevant articles concerning sustainable PSC and Industry 4.0, taken from peer-reviewed academic journals over a decade (2008–2018). Based on content analysis, we find that the major challenges that inhibit inclusion of sustainability in the PSCs |
doi_str_mv | 10.1016/j.psep.2018.06.031 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2132231134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0957582018303720</els_id><sourcerecordid>2132231134</sourcerecordid><originalsourceid>FETCH-LOGICAL-c501t-2a74b4da01242596cab68e32a512a37f278e0843708f6f70ce80c7b24931f5b53</originalsourceid><addsrcrecordid>eNp9kEtPwzAQhC0EEuXxBzhZ4pywfiROEReEeFSqBAc4W46zUV21ibEdUP89LuXMaVfamdnRR8gVg5IBq2_WpY_oSw6sKaEuQbAjMmNKykJU8-aYzGBeqaJqOJySsxjXAMC4YjOyfVuZsDV0MXRTTGFHZQm3dOkSBpOmgDTgl8NvaoYurxFNsCs6ej-GNA0uOYzUDTRmr3GDaTdI_W-gxSk5azb55P1mR-0q3-MFOenNJuLl3zwnH0-P7w8vxfL1efFwvyxsBSwV3CjZys7kjpJX89qatm5QcFMxboTquWoQGikUNH3dK7DYgFUtl3PB-qqtxDm5PuT6MH5OGJNej1MY8kvNmeBcMCZkVvGDyoYxxoC99sFtTdhpBnqPVa_1HqveY9VQ64w1m-4OJsz9M5qgo3U4WOxcQJt0N7r_7D8vt4HJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2132231134</pqid></control><display><type>article</type><title>Pharma Industry 4.0: Literature review and research opportunities in sustainable pharmaceutical supply chains</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><creator>Ding, Baoyang</creator><creatorcontrib>Ding, Baoyang</creatorcontrib><description>•The sustainable pharmaceutical supply chain (PSC) management is still a niche area for both pharmaceutical and supply chain management researchers. The exploitation of the emerging technologies of Pharma Industry 4.0 facilitates sustainable value creation, leads to more agile, smart and personalised pharma industry.•A more sustainable PSC should be applied to match future smart operations and management of the pharmaceutical products across the entire life cycle, from manufacturing to end-users. However, both internal and external inhibitors should be overcome, which include: high investment; poor support by senior managers; lack of well training expertise; enforcement of regulations; the insufficient coordination and communication beyond the boundaries of the PSC; the paucity of assessment systems and benchmarks; ineffective business incentives; poor end-customer awareness.•The sustainable PSC can benefit from Industry 4.0 in terms of four main aspects: enhancing the flexibility of the PSC for patient-centric drug supplies; improving the effectiveness of coordination and communication across different entities; reducing waste and pollution at different stages; and enabling a more autonomous decision-making process for supply chain managers, especially for healthcare sectors.•Future research interest can concentrate on: cross-linking coordination and cooperation, eco-friendly end-of-life products disposal, proactive recall management, new benchmarks and measurement of sustainable performance, new regulation system design, and effects of incentives for sustainable activities.
The exploitation of the emerging technologies of Pharma Industry 4.0 facilitates sustainable value creation, leads to more agile, smart and personalised pharma industry, and thereby, in the long-run, enables pharma companies to obtain competitive advantages. A more sustainable pharmaceutical supply chain (PSC) should be implemented to match future operations and management of the pharmaceutical products across the entire life cycle. The main purpose of this study is to identify the potential sustainability barriers of PSC and to investigate how Industry 4.0 can be applied in the sustainable PSC paradigms. This paper systematically reviews 33 relevant articles concerning sustainable PSC and Industry 4.0, taken from peer-reviewed academic journals over a decade (2008–2018). Based on content analysis, we find that the major challenges that inhibit inclusion of sustainability in the PSCs are: high costs and time consumption, little expertise and training, enforcement of regulations, the paucity of business incentives, ineffective collaborations and coordination across the PSC, lack of objective benchmarks, and poor end-customer awareness. The technologies and innovations based on Industry 4.0 can solve these barriers with regards to four aspects: enhancing the flexibility of the PSC for patient-centric drug supplies; improving the effectiveness of coordination and communication across different entities within the PSC; mitigating waste and pollution at different stages; and enabling a more autonomous decision-making process for supply chain managers. Our analysis reveals that future research interest should focus on: cross-linking coordination and cooperation, eco-friendly end-of-life products disposal, proactive product recall management, new benchmarks and measurement of sustainable performance, new regulation system design, and effects of incentives for sustainable activities.</description><identifier>ISSN: 0957-5820</identifier><identifier>EISSN: 1744-3598</identifier><identifier>DOI: 10.1016/j.psep.2018.06.031</identifier><language>eng</language><publisher>Rugby: Elsevier B.V</publisher><subject>Agile manufacturing ; Benchmarks ; Content analysis ; Crosslinking ; Decision analysis ; Decision making ; Exploitation ; Incentives ; Industrial Revolution ; Industry 4.0 ; Innovations ; Life cycle engineering ; Life cycles ; Literature reviews ; Pharmaceutical ; Pharmaceutical industry ; Pharmaceuticals ; Product recalls ; Supply chain ; Supply chains ; Sustainability ; Sustainability management ; Sustainable operations ; Systems design ; Waste disposal</subject><ispartof>Process safety and environmental protection, 2018-10, Vol.119, p.115-130</ispartof><rights>2018 Institution of Chemical Engineers</rights><rights>Copyright Elsevier Science Ltd. Oct 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c501t-2a74b4da01242596cab68e32a512a37f278e0843708f6f70ce80c7b24931f5b53</citedby><cites>FETCH-LOGICAL-c501t-2a74b4da01242596cab68e32a512a37f278e0843708f6f70ce80c7b24931f5b53</cites><orcidid>0000-0002-2014-2298</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.psep.2018.06.031$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids></links><search><creatorcontrib>Ding, Baoyang</creatorcontrib><title>Pharma Industry 4.0: Literature review and research opportunities in sustainable pharmaceutical supply chains</title><title>Process safety and environmental protection</title><description>•The sustainable pharmaceutical supply chain (PSC) management is still a niche area for both pharmaceutical and supply chain management researchers. The exploitation of the emerging technologies of Pharma Industry 4.0 facilitates sustainable value creation, leads to more agile, smart and personalised pharma industry.•A more sustainable PSC should be applied to match future smart operations and management of the pharmaceutical products across the entire life cycle, from manufacturing to end-users. However, both internal and external inhibitors should be overcome, which include: high investment; poor support by senior managers; lack of well training expertise; enforcement of regulations; the insufficient coordination and communication beyond the boundaries of the PSC; the paucity of assessment systems and benchmarks; ineffective business incentives; poor end-customer awareness.•The sustainable PSC can benefit from Industry 4.0 in terms of four main aspects: enhancing the flexibility of the PSC for patient-centric drug supplies; improving the effectiveness of coordination and communication across different entities; reducing waste and pollution at different stages; and enabling a more autonomous decision-making process for supply chain managers, especially for healthcare sectors.•Future research interest can concentrate on: cross-linking coordination and cooperation, eco-friendly end-of-life products disposal, proactive recall management, new benchmarks and measurement of sustainable performance, new regulation system design, and effects of incentives for sustainable activities.
The exploitation of the emerging technologies of Pharma Industry 4.0 facilitates sustainable value creation, leads to more agile, smart and personalised pharma industry, and thereby, in the long-run, enables pharma companies to obtain competitive advantages. A more sustainable pharmaceutical supply chain (PSC) should be implemented to match future operations and management of the pharmaceutical products across the entire life cycle. The main purpose of this study is to identify the potential sustainability barriers of PSC and to investigate how Industry 4.0 can be applied in the sustainable PSC paradigms. This paper systematically reviews 33 relevant articles concerning sustainable PSC and Industry 4.0, taken from peer-reviewed academic journals over a decade (2008–2018). Based on content analysis, we find that the major challenges that inhibit inclusion of sustainability in the PSCs are: high costs and time consumption, little expertise and training, enforcement of regulations, the paucity of business incentives, ineffective collaborations and coordination across the PSC, lack of objective benchmarks, and poor end-customer awareness. The technologies and innovations based on Industry 4.0 can solve these barriers with regards to four aspects: enhancing the flexibility of the PSC for patient-centric drug supplies; improving the effectiveness of coordination and communication across different entities within the PSC; mitigating waste and pollution at different stages; and enabling a more autonomous decision-making process for supply chain managers. Our analysis reveals that future research interest should focus on: cross-linking coordination and cooperation, eco-friendly end-of-life products disposal, proactive product recall management, new benchmarks and measurement of sustainable performance, new regulation system design, and effects of incentives for sustainable activities.</description><subject>Agile manufacturing</subject><subject>Benchmarks</subject><subject>Content analysis</subject><subject>Crosslinking</subject><subject>Decision analysis</subject><subject>Decision making</subject><subject>Exploitation</subject><subject>Incentives</subject><subject>Industrial Revolution</subject><subject>Industry 4.0</subject><subject>Innovations</subject><subject>Life cycle engineering</subject><subject>Life cycles</subject><subject>Literature reviews</subject><subject>Pharmaceutical</subject><subject>Pharmaceutical industry</subject><subject>Pharmaceuticals</subject><subject>Product recalls</subject><subject>Supply chain</subject><subject>Supply chains</subject><subject>Sustainability</subject><subject>Sustainability management</subject><subject>Sustainable operations</subject><subject>Systems design</subject><subject>Waste disposal</subject><issn>0957-5820</issn><issn>1744-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kEtPwzAQhC0EEuXxBzhZ4pywfiROEReEeFSqBAc4W46zUV21ibEdUP89LuXMaVfamdnRR8gVg5IBq2_WpY_oSw6sKaEuQbAjMmNKykJU8-aYzGBeqaJqOJySsxjXAMC4YjOyfVuZsDV0MXRTTGFHZQm3dOkSBpOmgDTgl8NvaoYurxFNsCs6ej-GNA0uOYzUDTRmr3GDaTdI_W-gxSk5azb55P1mR-0q3-MFOenNJuLl3zwnH0-P7w8vxfL1efFwvyxsBSwV3CjZys7kjpJX89qatm5QcFMxboTquWoQGikUNH3dK7DYgFUtl3PB-qqtxDm5PuT6MH5OGJNej1MY8kvNmeBcMCZkVvGDyoYxxoC99sFtTdhpBnqPVa_1HqveY9VQ64w1m-4OJsz9M5qgo3U4WOxcQJt0N7r_7D8vt4HJ</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Ding, Baoyang</creator><general>Elsevier B.V</general><general>Elsevier Science Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7ST</scope><scope>7TB</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>KR7</scope><scope>SOI</scope><orcidid>https://orcid.org/0000-0002-2014-2298</orcidid></search><sort><creationdate>20181001</creationdate><title>Pharma Industry 4.0: Literature review and research opportunities in sustainable pharmaceutical supply chains</title><author>Ding, Baoyang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c501t-2a74b4da01242596cab68e32a512a37f278e0843708f6f70ce80c7b24931f5b53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Agile manufacturing</topic><topic>Benchmarks</topic><topic>Content analysis</topic><topic>Crosslinking</topic><topic>Decision analysis</topic><topic>Decision making</topic><topic>Exploitation</topic><topic>Incentives</topic><topic>Industrial Revolution</topic><topic>Industry 4.0</topic><topic>Innovations</topic><topic>Life cycle engineering</topic><topic>Life cycles</topic><topic>Literature reviews</topic><topic>Pharmaceutical</topic><topic>Pharmaceutical industry</topic><topic>Pharmaceuticals</topic><topic>Product recalls</topic><topic>Supply chain</topic><topic>Supply chains</topic><topic>Sustainability</topic><topic>Sustainability management</topic><topic>Sustainable operations</topic><topic>Systems design</topic><topic>Waste disposal</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ding, Baoyang</creatorcontrib><collection>CrossRef</collection><collection>Environment Abstracts</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Civil Engineering Abstracts</collection><collection>Environment Abstracts</collection><jtitle>Process safety and environmental protection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ding, Baoyang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharma Industry 4.0: Literature review and research opportunities in sustainable pharmaceutical supply chains</atitle><jtitle>Process safety and environmental protection</jtitle><date>2018-10-01</date><risdate>2018</risdate><volume>119</volume><spage>115</spage><epage>130</epage><pages>115-130</pages><issn>0957-5820</issn><eissn>1744-3598</eissn><abstract>•The sustainable pharmaceutical supply chain (PSC) management is still a niche area for both pharmaceutical and supply chain management researchers. The exploitation of the emerging technologies of Pharma Industry 4.0 facilitates sustainable value creation, leads to more agile, smart and personalised pharma industry.•A more sustainable PSC should be applied to match future smart operations and management of the pharmaceutical products across the entire life cycle, from manufacturing to end-users. However, both internal and external inhibitors should be overcome, which include: high investment; poor support by senior managers; lack of well training expertise; enforcement of regulations; the insufficient coordination and communication beyond the boundaries of the PSC; the paucity of assessment systems and benchmarks; ineffective business incentives; poor end-customer awareness.•The sustainable PSC can benefit from Industry 4.0 in terms of four main aspects: enhancing the flexibility of the PSC for patient-centric drug supplies; improving the effectiveness of coordination and communication across different entities; reducing waste and pollution at different stages; and enabling a more autonomous decision-making process for supply chain managers, especially for healthcare sectors.•Future research interest can concentrate on: cross-linking coordination and cooperation, eco-friendly end-of-life products disposal, proactive recall management, new benchmarks and measurement of sustainable performance, new regulation system design, and effects of incentives for sustainable activities.
The exploitation of the emerging technologies of Pharma Industry 4.0 facilitates sustainable value creation, leads to more agile, smart and personalised pharma industry, and thereby, in the long-run, enables pharma companies to obtain competitive advantages. A more sustainable pharmaceutical supply chain (PSC) should be implemented to match future operations and management of the pharmaceutical products across the entire life cycle. The main purpose of this study is to identify the potential sustainability barriers of PSC and to investigate how Industry 4.0 can be applied in the sustainable PSC paradigms. This paper systematically reviews 33 relevant articles concerning sustainable PSC and Industry 4.0, taken from peer-reviewed academic journals over a decade (2008–2018). Based on content analysis, we find that the major challenges that inhibit inclusion of sustainability in the PSCs are: high costs and time consumption, little expertise and training, enforcement of regulations, the paucity of business incentives, ineffective collaborations and coordination across the PSC, lack of objective benchmarks, and poor end-customer awareness. The technologies and innovations based on Industry 4.0 can solve these barriers with regards to four aspects: enhancing the flexibility of the PSC for patient-centric drug supplies; improving the effectiveness of coordination and communication across different entities within the PSC; mitigating waste and pollution at different stages; and enabling a more autonomous decision-making process for supply chain managers. Our analysis reveals that future research interest should focus on: cross-linking coordination and cooperation, eco-friendly end-of-life products disposal, proactive product recall management, new benchmarks and measurement of sustainable performance, new regulation system design, and effects of incentives for sustainable activities.</abstract><cop>Rugby</cop><pub>Elsevier B.V</pub><doi>10.1016/j.psep.2018.06.031</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-2014-2298</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0957-5820 |
ispartof | Process safety and environmental protection, 2018-10, Vol.119, p.115-130 |
issn | 0957-5820 1744-3598 |
language | eng |
recordid | cdi_proquest_journals_2132231134 |
source | Elsevier ScienceDirect Journals Complete - AutoHoldings |
subjects | Agile manufacturing Benchmarks Content analysis Crosslinking Decision analysis Decision making Exploitation Incentives Industrial Revolution Industry 4.0 Innovations Life cycle engineering Life cycles Literature reviews Pharmaceutical Pharmaceutical industry Pharmaceuticals Product recalls Supply chain Supply chains Sustainability Sustainability management Sustainable operations Systems design Waste disposal |
title | Pharma Industry 4.0: Literature review and research opportunities in sustainable pharmaceutical supply chains |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T08%3A39%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharma%20Industry%204.0:%20Literature%20review%20and%20research%20opportunities%20in%20sustainable%20pharmaceutical%20supply%20chains&rft.jtitle=Process%20safety%20and%20environmental%20protection&rft.au=Ding,%20Baoyang&rft.date=2018-10-01&rft.volume=119&rft.spage=115&rft.epage=130&rft.pages=115-130&rft.issn=0957-5820&rft.eissn=1744-3598&rft_id=info:doi/10.1016/j.psep.2018.06.031&rft_dat=%3Cproquest_cross%3E2132231134%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2132231134&rft_id=info:pmid/&rft_els_id=S0957582018303720&rfr_iscdi=true |